Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Operations (2016 - 2025)

Corcept Therapeutics' Cash from Operations history spans 10 years, with the latest figure at 38448000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 35.98% year-over-year to 38448000.0; the TTM value through Dec 2025 reached 141996000.0, down 28.39%, while the annual FY2025 figure was 141996000.0, 28.39% down from the prior year.
  • Cash from Operations for Q4 2025 was 38448000.0 at Corcept Therapeutics, down from 54481000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 73293000.0 in Q3 2024 and bottomed at 5128000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 39818000.0 (2024), against an average of 37759350.0.
  • The largest annual shift saw Cash from Operations plummeted 83.44% in 2023 before it skyrocketed 986.24% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 49427000.0 in 2021, then tumbled by 32.45% to 33388000.0 in 2022, then tumbled by 83.44% to 5529000.0 in 2023, then surged by 986.24% to 60058000.0 in 2024, then crashed by 35.98% to 38448000.0 in 2025.
  • Per Business Quant, the three most recent readings for CORT's Cash from Operations are 38448000.0 (Q4 2025), 54481000.0 (Q3 2025), and 43939000.0 (Q2 2025).